TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+4.56%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.67B
AUM Growth
+$2.67B
(+1.6%)
Cap. Flow
-$9.43M
Cap. Flow
% of AUM
-0.35%
Top 10 Holdings %
Top 10 Hldgs %
35.39%
Holding
233
New
11
Increased
50
Reduced
32
Closed
29
Top Buys
| 1 |
AbbVie
ABBV
|
$29.9M |
| 2 |
Illumina
ILMN
|
$20.5M |
| 3 |
Steris
STE
|
$20.4M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$18.9M |
| 5 |
Humana
HUM
|
$15.5M |
Top Sells
| 1 |
Johnson & Johnson
JNJ
|
$42.2M |
| 2 |
Thermo Fisher Scientific
TMO
|
$33.8M |
| 3 |
UnitedHealth
UNH
|
$29.4M |
| 4 |
IMMU
Immunomedics Inc
IMMU
|
$23.3M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$20.7M |
Sector Composition
| 1 | Healthcare | 95.21% |
| 2 | Real Estate | 2.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Amgen
AMGN
$155B
| $155M | 5.79% | 608,218 -3,744 | -0.6% | -$952K |
|
2
Regeneron Pharmaceuticals
REGN
$61.5B
| $116M | 4.35% | 207,388 +19,453 | +10% | +$10.9M |
|
|
3
Vertex Pharmaceuticals
VRTX
$100B
| $109M | 4.09% | 401,360 -75,970 | -16% | -$20.7M |
|
4
Gilead Sciences
GILD
$140B
| $104M | 3.89% | 1,643,683 +62,657 | +4% | +$3.96M |
|
5
Merck
MRK
$210B
| $87.7M | 3.28% | 1,056,706 +85,210 | +9% | +$7.07M |
|
|
6
Illumina
ILMN
$15.8B
| $86.9M | 3.26% | 281,054 +66,403 | +31% | +$20.5M |
|
|
7
Johnson & Johnson
JNJ
$427B
| $81.4M | 3.05% | 546,805 -283,226 | -34% | -$42.2M |
|
|
8
AbbVie
ABBV
$372B
| $76.6M | 2.87% | 874,720 +340,995 | +64% | +$29.9M |
|
|
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
| $66M | 2.47% | 337,204 +96,645 | +40% | +$18.9M |
|
10
Pfizer
PFE
$141B
| $62.2M | 2.33% | 1,695,768 +39,220 | +2% | +$1.44M |
|
11
Biogen
BIIB
$19.4B
| $60.6M | 2.27% | 213,753 -19,846 | -8% | -$5.63M |
|
|
12
UnitedHealth
UNH
$281B
| $57.9M | 2.17% | 185,735 -94,416 | -34% | -$29.4M |
|
13
Bristol-Myers Squibb
BMY
$96B
| $57M | 2.14% | 945,140 -32,365 | -3% | -$1.95M |
|
14
Medtronic
MDT
$119B
| $55.6M | 2.08% | 534,914 +59,425 | +12% | +$6.18M |
|
|
HZNP
15
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $46.9M | 1.76% | 603,684 +193,531 | +47% | +$15M |
|
16
Abbott
ABT
$231B
| $40.2M | 1.51% | 369,573 -116,677 | -24% | -$12.7M |
|
|
17
Humana
HUM
$36.5B
| $35.6M | 1.33% | 86,007 +37,501 | +77% | +$15.5M |
|
18
Stryker
SYK
$150B
| $32.9M | 1.23% | 157,830 -6,400 | -4% | -$1.33M |
|
19
Moderna
MRNA
$9.37B
| $32.6M | 1.22% | 460,359 -32,147 | -7% | -$2.27M |
|
20
Becton Dickinson
BDX
$55.3B
| $30.6M | 1.15% | 131,723 +53,969 | +69% | +$12.6M |
|
|
ALXN
21
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $30.5M | 1.14% | 266,791 -117,918 | -31% | -$13.5M |
|
22
Sarepta Therapeutics
SRPT
$1.78B
| $29M | 1.09% | 206,487 +66,358 | +47% | +$9.32M |
|
23
Boston Scientific
BSX
$156B
| $28.3M | 1.06% | 741,296 +96,361 | +15% | +$3.68M |
|
24
Exelixis
EXEL
$10.1B
| $26.8M | 1% | 1,095,117 +161,168 | +17% | +$3.94M |
|
25
Centene
CNC
$14.3B
| $26.7M | 1% | 458,313 +170,119 | +59% | +$9.92M |
|